Study guide

30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves

Key Takeaways Explain This Topic AI

Incidence counts new cases in a population at risk over time, prevalence counts all existing cases at a point; prevalence is roughly incidence times duration.

Relative risk comes from cohort studies and the odds ratio from case-control studies; NNT is 1 divided by the absolute risk reduction.

An epidemic is the occurrence of cases clearly in excess of the usual expected level in a place and time; a single case of a disease long absent, such as polio, can signal an outbreak.

The case fatality rate is deaths from a disease divided by the number of cases of that disease, a measure of severity, not of risk in the population.

In an outbreak, control measures are started as soon as the source is suspected, without waiting for the analytic study to finish.

Last updated: October 2026

Why this area matters

The TOS asks you to:

  • declare outbreaks and epidemics using available parameters;
  • carry out interventions during outbreaks ;
  • monitor outbreaks until they are declared over ;

interpret epidemiologic measures.

Dengue, measles, cholera, typhoid, leptospirosis and food-poisoning outbreaks are frequent in the Philippines. The municipal health officer is often the first to recognize them and must report them under RA 11332 .

Measures of Disease Occurrence: Incidence vs. Prevalence

Quantifying disease in populations requires clear differentiation between newly emerging cases and existing morbidity.

Incidence: Quantifying New Events

Incidence measures the rate at which newly diagnosed cases develop in a susceptible population initially free of the target disease over a defined observation window:

Cumulative Incidence (Incidence Proportion / Attack Rate): The proportion of initially at-risk individuals who develop the condition over a specified timeframe:

Cumulative Incidence = Number of new incident cases during time period Total population at risk at study baseline \text{Cumulative Incidence} = \frac{\text{Number of new incident cases during time period}}{\text{Total population at risk at study baseline}} Cumulative Incidence = Total population at risk at study baseline Number of new incident cases during time period ​

Incidence Rate (Incidence Density): The true rate of disease occurrence taking into account variable periods of person-time observation:

Incidence Rate = Number of new incident cases Total person-time of observation at risk \text{Incidence Rate} = \frac{\text{Number of new incident cases}}{\text{Total person-time of observation at risk}} Incidence Rate = Total person-time of observation at risk Number of new incident cases ​

Denominator note: Individuals who already possess the disease, who are biologically immune, or who have undergone bilateral organ resection (e.g., prior bilateral oophorectomy in ovarian cancer studies) must be strictly excluded from the baseline population at risk.

Prevalence: Quantifying Total Disease Burden

Prevalence reflects the total burden of disease in a designated population at a specific cross-section of time, encompassing both newly incident cases and pre-existing chronic conditions:

Point Prevalence: The proportion of a population affected by disease at a single precise instant in time:

Point Prevalence = Total existing cases (new + old) at a specific date Total population at that specific date \text{Point Prevalence} = \frac{\text{Total existing cases (new + old) at a specific date}}{\text{Total population at that specific date}} Point Prevalence = Total population at that specific date Total existing cases (new + old) at a specific date ​

Period Prevalence: The proportion of individuals possessing the disease at any point during a defined interval (e.g., calendar year 2026).

The Steady-State Relationship Formula

In a stable population where disease incidence and duration remain constant over time (steady-state dynamics) and prevalence is relatively low ( P < 0.10 P < 0.10 P < 0.10 ), prevalence is approximately equal to the product of incidence and the mean duration of illness:

P ≈ I × D P \approx I \times D P ≈ I × D

Where:

P = Prevalence (dimensionless proportion) P = \text{Prevalence (dimensionless proportion)} P = Prevalence (dimensionless proportion)

I = Incidence rate (cases per unit person-time) I = \text{Incidence rate (cases per unit person-time)} I = Incidence rate (cases per unit person-time)

D = Average duration of illness (time) D = \text{Average duration of illness (time)} D = Average duration of illness (time)

High-Yield Board Exam Traps: Dynamics of P = I x D

Clinical / Therapeutic Event Effect on Incidence ( I I I ) Effect on Duration ( D D D ) Net Effect on Prevalence ( P P P )

Introduction of a curative therapeutic drug (e.g., penicillin for syphilis) Unchanged initially Markedly decreased Decreased (rapid cure clears active case pool)

Introduction of a life-prolonging maintenance drug (e.g., antiretroviral therapy for HIV; insulin for Type 1 diabetes) Unchanged directly Markedly increased Increased (patients survive longer with chronic disease)

Introduction of a highly effective prophylactic vaccine (e.g., HPV, measles) Decreased Unchanged Decreased (fewer incident cases enter the pool)

Rapidly lethal virulent mutation / high case fatality Unchanged or increased Markedly decreased Decreased (patients perish before accumulation)

Improved diagnostic sensitivity and screening Increased (transiently) Unchanged Increased (uncovers latent pre-existing cases)

Measures of Association and Public Health Impact

Measures of association quantify the strength of statistical dependency between an exposure factor and a health outcome.

The Standard 2x2 Contingency Table

  • Exposure Status Disease Present ( D + D+ D + ) Disease Absent ( D − D- D − ) Total
  • Exposed ( E + E+ E + ) a a a (exposed cases) b b b (exposed non-cases) a + b a + b a + b
  • Unexposed ( E − E- E − ) c c c (unexposed cases) d d d (unexposed non-cases) c + d c + d c + d
  • Total a + c a + c a + c b + d b + d b + d N = a + b + c + d N = a + b + c + d N = a + b + c + d
  • Relative Risk (Risk Ratio, RR)

Calculated exclusively in cohort studies and randomized controlled trials (RCTs) where baseline incidence rates in exposed and unexposed cohorts can be directly measured:

R R = Incidence in exposed cohort ( I e ) Incidence in unexposed cohort ( I u ) = a / ( a + b ) c / ( c + d ) RR = \frac{\text{Incidence in exposed cohort } (I_e)}{\text{Incidence in unexposed cohort } (I_u)} = \frac{a / (a + b)}{c / (c + d)} RR = Incidence in unexposed cohort ( I u ​ ) Incidence in exposed cohort ( I e ​ ) ​ = c / ( c + d ) a / ( a + b ) ​

Interpretation:

R R = 1.0 RR = 1.0 RR = 1.0 : Null association; risk in exposed equals risk in unexposed.

R R > 1.0 RR > 1.0 RR > 1.0 : Positive association; exposure increases the risk of disease (e.g., R R = 3.0 RR = 3.0 RR = 3.0 indicates exposed individuals have 3 times the risk of unexposed individuals).

R R < 1.0 RR < 1.0 RR < 1.0 : Negative/protective association; exposure reduces disease risk (e.g., R R = 0.40 RR = 0.40 RR = 0.40 indicates a 60% risk reduction, characteristic of effective vaccination).

Odds Ratio (OR)

Calculated in case-control studies (where subjects are recruited based on disease outcome, precluding direct calculation of baseline population incidence) and cross-sectional studies:

O R = Odds of exposure in cases Odds of exposure in controls = a / c b / d = a × d b × c OR = \frac{\text{Odds of exposure in cases}}{\text{Odds of exposure in controls}} = \frac{a / c}{b / d} = \frac{a \times d}{b \times c} OR = Odds of exposure in controls Odds of exposure in cases ​ = b / d a / c ​ = b × c a × d ​

The Rare Disease Assumption: In case-control studies, the Odds Ratio closely approximates the Relative Risk ( O R ≈ R R OR \approx RR OR ≈ RR ) when the disease under investigation is rare in the general population (prevalence < 5 % < 5\% < 5% ). Under this condition, a a a is negligible relative to b b b ( a + b ≈ b a + b \approx b a + b ≈ b ), and c c c is negligible relative to d d d ( c + d ≈ d c + d \approx d c + d ≈ d ), making the mathematical ratio identical.

Absolute Risk Reduction (ARR) & Attributable Risk (AR)

Attributable Risk (Risk Difference, AR) represents the absolute excess rate of disease directly attributable to the exposure among exposed individuals:

A R = I e − I u = a a + b − c c + d AR = I_e - I_u = \frac{a}{a + b} - \frac{c}{c + d} A R = I e ​ − I u ​ = a + b a ​ − c + d c ​

When evaluating a beneficial therapeutic or preventive intervention in an RCT, this absolute difference is termed the Absolute Risk Reduction (ARR) :

A R R = I control − I experimental ARR = I_{\text{control}} - I_{\text{experimental}} A RR = I control ​ − I experimental ​

Relative Risk Reduction (RRR) and Attributable Risk Percent (AR%)

Quantifies the proportion of disease in the exposed cohort that would be eliminated if the exposure were completely abolished:

A R % = I e − I u I e × 100 % = R R − 1 R R × 100 % AR\% = \frac{I_e - I_u}{I_e} \times 100\% = \frac{RR - 1}{RR} \times 100\% A R % = I e ​ I e ​ − I u ​ ​ × 100% = RR RR − 1 ​ × 100%

For therapeutic trials:

R R R = I control − I experimental I control × 100 % = 1 − R R RRR = \frac{I_{\text{control}} - I_{\text{experimental}}}{I_{\text{control}}} \times 100\% = 1 - RR RRR = I control ​ I control ​ − I experimental ​ ​ × 100% = 1 − RR

Number Needed to Treat (NNT) and Number Needed to Harm (NNH)

The Number Needed to Treat (NNT) represents the number of patients who must receive a specific therapeutic intervention over a defined time period to prevent one additional adverse clinical outcome:

N N T = 1 A R R = 1 I control − I experimental NNT = \frac{1}{ARR} = \frac{1}{I_{\text{control}} - I_{\text{experimental}}} NNT = A RR 1 ​ = I control ​ − I experimental ​ 1 ​

The Number Needed to Harm (NNH) represents the number of patients exposed to a hazardous agent or adverse drug reaction required to produce one additional adverse event:

N N H = 1 A R I = 1 I exposed − I unexposed NNH = \frac{1}{ARI} = \frac{1}{I_{\text{exposed}} - I_{\text{unexposed}}} NN H = A R I 1 ​ = I exposed ​ − I unexposed ​ 1 ​

Strict Board Exam Calculation Rule: NNT and NNH values are always rounded upward to the nearest whole integer (e.g., an NNT of 12.1 is reported as 13 patients), because treating 12 patients would achieve sub-threshold clinical benefit.

Commonly used rates and levels of disease

  • Measure Definition
  • Crude death rate Deaths in a year per 1,000 mid-year population
  • Cause-specific death rate Deaths from a cause per 100,000 population
  • Case fatality rate Deaths from a disease divided by the cases of that disease, times 100 (measures severity )
  • Attack rate Cases divided by the population at risk during an outbreak (a cumulative incidence)

Secondary attack rate Cases among susceptible contacts after exposure to a primary case divided by all susceptible contacts (measures contagiousness)

  • Proportionate mortality Deaths from a cause divided by all deaths, times 100
  • Age-adjusted (standardized) rate Removes the effect of different age structures when comparing populations

Levels of disease occurrence:

  • sporadic : occasional cases;
  • endemic : the usual, constant presence in an area, such as malaria in Palawan;
  • hyperendemic : persistently high levels;
  • epidemic or outbreak : occurrence clearly in excess of what is expected for that place, time and population;

pandemic : an epidemic across several countries or continents.

Detecting an epidemic: the expected level is set from previous years, for example with an epidemic threshold such as the 5-year mean plus 2 standard deviations. A single case of a disease that is absent or targeted for elimination (polio, diphtheria in a vaccinated area, human avian influenza) is treated as an outbreak.

Declaring an outbreak over: usually after two maximum incubation periods pass without new cases.

Herd immunity: when enough of a population is immune, transmission stops even among the unvaccinated. The threshold is about 1 minus 1/R0 . For measles, with an R0 of 12 to 18, about 95% coverage is needed.

Disease Surveillance in the Philippines: PIDSR Framework

Disease surveillance is governed nationally by the Philippine Integrated Disease Surveillance and Response (PIDSR) system under the Department of Health (DOH) Epidemiology Bureau, anchored by the legal authority of Republic Act No. 11332 ( Mandatory Reporting of Notifiable Diseases and Health Events of Public Health Concern Act ).

Statutory Disease Categories under RA 11332

The revised Implementing Rules and Regulations of RA 11332 (2020) list the notifiable diseases in two categories:

Category Reporting deadline Diseases and syndromes

Category I (immediately notifiable) Report to the local, regional and national epidemiology and surveillance units within 24 hours of detection Acute flaccid paralysis; adverse event following immunization; anthrax; COVID-19; hand, foot and mouth disease; human avian influenza; measles; meningococcal disease; MERS; neonatal tetanus; paralytic shellfish poisoning ; rabies; SARS

Category II (weekly notifiable) Report every Friday Acute bloody diarrhea; acute encephalitis syndrome; acute hemorrhagic fever syndrome; acute viral hepatitis; bacterial meningitis; cholera; dengue; diphtheria; influenza-like illness; leptospirosis; malaria; non-neonatal tetanus; pertussis; typhoid and paratyphoid fever

Any cluster or unusual event of public health concern is reported at once through event-based surveillance. Failure to report, or non-cooperation with authorities, is penalized under RA 11332. The penalty is a fine of 20,000 to 50,000 pesos, imprisonment of 1 to 6 months, or both.

How surveillance works in practice:

PIDSR uses disease reporting units : hospitals, RHUs and clinics, staffed by surveillance officers.

Epidemiology and surveillance units (municipal or city, provincial and regional) collect, analyze and act on reports.

Event-based surveillance captures unusual events and rumors.

Surveillance can be:

  • passive : routine reports from health facilities;
  • active : staff seek cases, for example AFP case-finding;
  • sentinel : selected sites, for example influenza;

syndromic , for example SPEED after disasters.

Outbreak Investigation: The 10-Step Standard Protocol

When epidemic clustering occurs, field epidemiologists execute a standardized 10-step protocol:

Prepare for Fieldwork: Secure administrative authorizations, assemble multidisciplinary investigation team, procure field diagnostic supplies and personal protective equipment (PPE).

Establish the Existence of an Outbreak: Confirm that observed case counts significantly exceed expected baseline endemic incidence for that specific geographic region and timeframe.

Verify the Diagnosis: Review clinical charts, interview attending clinicians, and collect biological specimens to verify etiologic diagnosis via reference laboratory testing.

Construct a Working Case Definition: Develop standardized criteria based on person, place, time, and clinical/laboratory features , categorizing cases as Confirmed , Probable , or Suspect .

Find Cases Systematically and Record Information: Conduct active case finding across clinics and communities; record demographic, clinical, and exposure details in a standardized line listing .

Perform Descriptive Epidemiology: Characterize the outbreak by time (epidemic curve), place (spot map of cases), and person (age, sex, attack rates by subgroup).

Develop Hypotheses: Formulate hypotheses regarding the source of the pathogen, vehicle of transmission, and exposure route based on descriptive data and biological plausibility.

Evaluate Hypotheses Analytically: Conduct an analytical observational study (a retrospective cohort study comparing attack rates and relative risks if the population is well-defined, e.g., a catered banquet; or a case-control study comparing odds ratios if the population is open and undefined).

Implement Immediate Control and Prevention Measures: Eliminate the source (e.g., close contaminated water wells, recall contaminated food), interrupt transmission (vector control, sanitary disinfection), and protect susceptible hosts (vaccination, chemoprophylaxis, barrier precautions). Critical rule: Control measures must be executed immediately when evidence emerges, without delaying for analytical study completion.

Communicate Findings and Initiate Ongoing Surveillance: Disseminate a comprehensive written report to public health authorities and the public; establish ongoing post-outbreak surveillance.

Epidemic Curve Patterns

Point Source Epidemic: Cases rise sharply, peak rapidly within a single incubation period, and decline gradually. Reflects simultaneous exposure of a cohort to a single common vehicle (e.g., staphylococcal enterotoxin food poisoning).

Continuous Common Source Epidemic: Cases rise gradually and maintain a prolonged plateau without a sharp peak, reflecting persistent ongoing exposure to a contaminated source (e.g., ongoing contamination of a municipal water reservoir).

Propagated (Person-to-Person) Epidemic: A series of progressively taller, undulating peaks separated by an average incubation period interval, reflecting successive waves of human-to-human transmission (e.g., measles, pertussis, SARS-CoV-2).

Typical vehicles of food and water outbreaks:

  • S. aureus and B. cereus : short incubation;
  • Salmonella ;
  • cholera and typhoid : contaminated water systems;

hepatitis A .

In a food-borne outbreak , food-specific attack rates are compared. The food with the largest difference in attack rate (or highest relative risk) between people who ate it and those who did not is the likely vehicle, especially if most cases ate it.